Regional Chemotherapy: Possibilities for Prevention and Treatment of Peritoneal Metastases from Gastric Cancer

  • H Sugarbaker
  • Published 2016

Abstract

Gastric cancer is the fourth most commonly diagnosed cancer in the world with a 5-year survival rate of 25% [1,2]. In follow-up, almost half of gastric cancer patients will develop peritoneal dissemination which results in a less than 5% 5-year survival rate [3–5]. Peritoneal metastases are a common finding in primary gastric cancer found in 5 to 20% of patients at the time of gastrectomy [6]. The peritoneum is also the most common location of first recurrence observed in about half of the patients [7]. Standard of care for treatment of primary or recurrence Paul H Sugarbaker* and Mei Li M Kwong Center for Gastrointestinal Malignancies, Medstar Washington Hospital Center, USA *Corresponding author: Paul H Sugarbaker, Center for Gastrointestinal Malignancies, Pro gram in Peritoneal Surface Oncology, Medstar Washington Hospital Center, 106 Irving St., NW, Suite 3900, Washington, DC 20010, USA. TEL: +1-202-877-3908; FAX: +1-202-8778602; Email: paul.sugarbaker@medstar.net

Cite this paper

@inproceedings{Sugarbaker2016RegionalCP, title={Regional Chemotherapy: Possibilities for Prevention and Treatment of Peritoneal Metastases from Gastric Cancer}, author={H Sugarbaker}, year={2016} }